Weaver Capital Management LLC Has $218,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Weaver Capital Management LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 66.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 387 shares of the biopharmaceutical company’s stock after selling 770 shares during the period. Weaver Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $218,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of REGN. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $31,000. Traub Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $38,000. Berbice Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the last quarter. Westside Investment Management Inc. boosted its stake in Regeneron Pharmaceuticals by 62.0% during the 2nd quarter. Westside Investment Management Inc. now owns 81 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 31 shares during the period. Finally, Ameritas Advisory Services LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $45,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.8%

Shares of REGN opened at $773.94 on Wednesday. The stock has a market cap of $81.34 billion, a price-to-earnings ratio of 18.53, a P/E/G ratio of 2.24 and a beta of 0.37. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $792.77. The company has a 50-day moving average price of $711.47 and a two-hundred day moving average price of $614.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the company posted $12.46 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. HSBC began coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $255.00 price target on the stock. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Scotiabank boosted their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Finally, UBS Group raised their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $779.45.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.